A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Clinical trial NCT07464145 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07464145
Sponsor: Relmada Therapeutics, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Bladder (Urothelial, Transitional Cell) Cancer Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder Urothelial Carcinoma Recurrent Urologic Cancer

Start date: 2026-06-01
Primary completion: 2029-09-01
Enrollment: 393

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.